FGF21类似物和MASLD:临床前和临床数据的总结
Chrysoula Boutari1, Achilleas Triantafyllou1, Lavrentis Papalavrentios1
1Fourth Medical Department, Hippokratio Hospital, Aristotle University of Thessaloniki, Greece.
Current pharmaceutical design
|August 6, 2025
概括
与代谢功能障碍相关的脂肪性肝病 (MASLD) 影响全球许多人. 纤维细胞生长因子 (FGF) 21类似物在临床试验中显示出治疗MASLD和代谢功能障碍相关的脂肪肝炎 (MASH) 的前景.
科学领域:
- 肝病学和代谢疾病
- 药理学和药物开发领域
背景情况:
- 代谢功能障碍相关的脂肪性肝病 (MASLD) 是最普遍的慢性肝病,与代谢综合征和肥胖症有很强的联系.
- 目前对MASLD和代谢功能障碍相关的脂肪肝炎 (MASH) 的治疗选择有限,这凸显了对有效治疗的迫切需要.
研究的目的:
- 审查关于纤维细胞生长因子 (FGF) 21类似物作为MASLD和MASH的潜在治疗方法的临床前和临床数据.
- 探索FGF21类似物在改善肝脏健康和全身新陈代谢方面的疗效.
主要方法:
- 关于肝脏疾病的FGF21类似物进行临床前研究的摘要.
- 对特定的FGF21类似物 (efruxifermin, pegozafermin, pegbelfermin, BOS-580) 的临床试验数据 (第二阶段) 的分析.
主要成果:
- FGF21类似物对肝功能,组织学和全身新陈代谢产生有利影响.
- 第二阶段试验显示,使用FGF21类似物显著改善了肝脂肪,脂肪肝炎和纤维化.
- 这些类似物表现出改善的药理动力学和药理动力学特征.
结论:
- FGF21类似物代表了对MASLD和MASH的有前途的治疗途径.
- 鉴于其减轻关键疾病标志物的潜力,FGF21类型的进一步临床开发是有必要的.
相关概念视频
01:28Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
01:16Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K